Komo

Alnylam Pharmaceuticals

Who are Alnylam Pharmaceuticals's decision-makers?

Alnylam Pharmaceuticals's official leadership and governance pages are the safest source for named executives.

Primary buyers
Finance, procurement, IT, security, operations, legal, and business leadership
Company status
Public company; Nasdaq: ALNY
HQ
Cambridge, MA
Category
RNA interference medicines
Decision style
Public-company buying committee
Best source
Official leadership or IR page
  • Alnylam Pharmaceuticals executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
  • Alnylam Pharmaceuticals finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
  • Alnylam Pharmaceuticals operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.

Who leads Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals's named leaders should be verified directly on the company's official leadership, governance, or investor-relations page.

Who owns buying decisions at Alnylam Pharmaceuticals?

The buying committee depends on the offer and usually spans finance, procurement, legal, IT/security, and the business owner.

How should sellers map the account?

Start with headquarters and public leadership, then map functional owners by product area, job posts, filings, partner announcements, and investor materials.

As of June 2026.Sources:Alnylam Pharmaceuticals official websiteAlnylam Pharmaceuticals investor relations or company newsBuiltWith public technology profile

Alnylam Pharmaceuticals — frequently asked questions

Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.